Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Invokana, canagliflozin, Date of authorisation: 15/11/2013, Revision: 27, Status: Authorised

EMA/PE/0000232894

EMA/PE/0000232896

Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 20 November 2025

EMA Cancer Medicines Forum (CMF) meeting with industry stakeholders on cancer treatment optimisation, Online, European Medicines Agency, Amsterdam, the Netherlands, from 14 November 2025, 13:30 (CET) to 14 November 2025, 17:30 (CET)

Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Date of authorisation: 27/06/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Trumenba, meningococcal group b vaccine (recombinant, adsorbed), Date of authorisation: 24/05/2017, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Date of authorisation: 22/01/2007, Revision: 47, Status: Authorised

List of European Union reference dates (EURD) and frequency of submission of periodic safety update reports (PSURs)